Clinical Validation of a Ray-Casting Analytical Dose Engine for Spot Scanning Proton Delivery Systems.


Journal

Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941

Informations de publication

Date de publication:
Historique:
entrez: 23 11 2019
pubmed: 23 11 2019
medline: 6 5 2020
Statut: ppublish

Résumé

To describe and validate the dose calculation algorithm of an independent second-dose check software for spot scanning proton delivery systems with full width at half maximum between 5 and 14 mm and with a negligible spray component. The analytical dose engine of our independent second-dose check software employs an altered pencil beam algorithm with 3 lateral Gaussian components. It was commissioned using Geant4 and validated by comparison to point dose measurements at several depths within spread-out Bragg peaks of varying ranges, modulations, and field sizes. Water equivalent distance was used to compensate for inhomogeneous geometry. Twelve patients representing different disease sites were selected for validation. Dose calculation results in water were compared to a fast Monte Carlo code and ionization chamber array measurements using dose planes and dose profiles as well as 2-dimensional-3-dimensional and 3-dimensional-3-dimensional γ-index analysis. Results in patient geometry were compared to Monte Carlo simulation using dose-volume histogram indices, 3-dimensional-3-dimensional γ-index analysis, and inpatient dose profiles. Dose engine model parameters were tuned to achieve 1.5% agreement with measured point doses. The in-water γ-index passing rates for the 12 patients using 3%/2 mm criteria were 99.5% ± 0.5% compared to Monte Carlo. The average inpatient γ-index analysis passing rate compared to Monte Carlo was 95.8% ± 2.9%. The average difference in mean dose to the clinical target volume between the dose engine and Monte Carlo was -0.4% ± 1.0%. For a typical plan, dose calculation time was 2 minutes on an inexpensive workstation. Following our commissioning process, the analytical dose engine was validated for all treatment sites except for the lung or for calculating dose-volume histogram indices involving point doses or critical structures immediately distal to target volumes. Monte Carlo simulations are recommended for these scenarios.

Identifiants

pubmed: 31755362
doi: 10.1177/1533033819887182
pmc: PMC6876166
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1533033819887182

Subventions

Organisme : NCI NIH HHS
ID : K25 CA168984
Pays : United States

Références

Phys Med Biol. 2012 Feb 21;57(4):983-97
pubmed: 22297324
Phys Med Biol. 2011 Dec 21;56(24):7725-35
pubmed: 22085829
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1157-1164
pubmed: 26025779
Phys Med Biol. 2005 Nov 7;50(21):5089-104
pubmed: 16237243
Med Phys. 2013 Apr;40(4):041723
pubmed: 23556893
Phys Med Biol. 2013 Jun 21;58(12):N171-80
pubmed: 23739230
Med Phys. 2007 Jan;34(1):193-8
pubmed: 17278504
Med Phys. 2017 Oct;44(10):5081-5088
pubmed: 28777447
J Appl Clin Med Phys. 2017 Nov;18(6):88-96
pubmed: 28921881
Phys Med Biol. 2014 Sep 21;59(18):5361-86
pubmed: 25157579
Med Phys. 1998 May;25(5):656-61
pubmed: 9608475
J Appl Clin Med Phys. 2014 Jul 08;15(4):4413
pubmed: 25207391
Phys Med Biol. 2018 Feb 09;63(4):045003
pubmed: 29339570
Phys Med Biol. 1996 Aug;41(8):1305-30
pubmed: 8858722
Med Phys. 1997 Dec;24(12):2024-33
pubmed: 9434986
Med Phys. 2018 Apr;45(4):e53-e83
pubmed: 29443390
Phys Med Biol. 2013 Sep 7;58(17):6193-204
pubmed: 23948730
Phys Med Biol. 2008 Mar 21;53(6):1545-62
pubmed: 18367787
Med Phys. 2019 Jan;46(1):5-14
pubmed: 30339270
Med Phys. 2010 Jan;37(1):154-63
pubmed: 20175477
Med Phys. 2016 Dec;43(12):6544
pubmed: 27908162
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):750-756
pubmed: 28843371
Phys Med Biol. 2005 Feb 7;50(3):541-61
pubmed: 15773729
Med Phys. 2016 Mar;43(3):1437-50
pubmed: 26936728
Med Phys. 2013 Dec;40(12):121708
pubmed: 24320494
Med Phys. 2009 Jul;36(7):2889-97
pubmed: 19673188
Phys Med Biol. 1999 Jan;44(1):27-41
pubmed: 10071873
Phys Med Biol. 2012 Mar 7;57(5):1147-58
pubmed: 22330090
Phys Med Biol. 2016 Jan 21;61(2):958-73
pubmed: 26738626
Phys Med Biol. 2015 Jul 21;60(14):5627-54
pubmed: 26146956
Med Phys. 2015 Jun;42(6):2967-78
pubmed: 26127050
Phys Med. 2015 Jul;31(5):484-92
pubmed: 26032003
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):79-84
pubmed: 25195989

Auteurs

James E Younkin (JE)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Danairis Hernandez Morales (DH)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Jiajian Shen (J)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Jie Shan (J)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Martin Bues (M)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Jarrod M Lentz (JM)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Steven E Schild (SE)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Joshua B Stoker (JB)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Xiaoning Ding (X)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Wei Liu (W)

Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH